tbuckley/cabot-search huggingface dataset:
The predictive value of the CA-125 modeled kinetic parameter KELIM is validated in 3 independent datasets (AGO-OVAR 7 &amp; 9; ICON 7 AGO/GINECO/GCIG trials)
Authors: B.M. You, O. Colomban, M. Tod, I.L. Ray-Coquard, A. Lortholary, A.C. Hardy-Bessard, A. Du Bois, J. Huober, W. Meier, C. Kurzeder, J. Pfisterer
Journal: Annals of Oncology (2016)
The Nephroprotective Effect of Folic Acid—Only a Matter of Homocysteine?
Authors: Claudio Pedone, Raffaele Antonelli Incalzi
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Involvement of Transcriptional Mediator Subunit TRAP220/MED1 in Action of Niche Cells to Support Hematopoietic Stem/Progenitor Cells
Authors: Kana Inoue, Akiko Sumitomo, Natsumi Hasegawa, Ayuko Kasai, Kenji Yonezawa, Norinaga Urahama, Mitsuhiro Ito
Journal: Blood (2008)
Abstract 12717: If Channel Blocker Ivabradine Counteracts Underisable Tachycardia in Patients Supported With Inotropic Agents
Authors: Ricardo Levin, Marcela Degrange, Alejandro Botbol, Matias Levin Degrange, Gabriel Perez Baztarrica, Flavio Salvagio, Rafael Porcile
Journal: Circulation (2015)

Introduction: The utilization of inotropic agents is usually linked to development of unappropriated and undesirable sinus tachycardia. That use also increases the myocardial oxygen consumption, could develop ischemic events and also has pro arrhythmic effects in coronary patients with acute heart failure, existing limited therapeutic options to face that situation. Hypothesis: The If channels blocker Ivabradine could be useful and safe for counteract the sinus tachycardia induced by inotropic agents and its undesirable effects without affecting the positive inotropic effect. Methods: Patients with ischemic-necrotic cardiomyopathy and low ejection fraction (under 35%) admitted for acute decompensation of heart failure with requirement of inotropic agents were prospectively and consecutively included. Patients with a rhythm different than sinus rhythm, impossibility for place a Swan-Ganz catheter or unable to use the oral route were excluded. Hemodynamic measurements with Pulmonary Artery catheters were performed before and three hours after oral administration of 15mg of Ivabradine. Results: The study included 52 patients (32 males and 20 females) with an average age of 65.6 years and an ejection fraction of 31.5% whe were under treatment with an average dose of 15 mcg/kg of Dobutamine. Three hours after started Ivabradine, it was observed a reduction of the heart rate from 123 +/-6 to 96+/-7 beats per minute (P=0.00002) with an increment of the systolic volume from 37.9+/-5 ml to 47.3+/-8 ml (P=0.00002) and the cardiac output from 4597 +/-550 ml/minute to 4825+/-535 ml/minute (P=0.041). No differences were observed nor in the filling pressures neither in the systemic or pulmonary resistances. There was a good clinical tolerance without evidence of hypotension, bradycardia, atrioventricular block episodes or need for transitory pacemaker . Conclusions: Ivabradine was an useful and safe intervention for controlling the undesirable sinus tachycardia linked to inotropic agents in patients with ischemic-necrotic cardiomyopathy. The drug didn’t affects the positive effect over contractility.
The Contact Activation Coagulation Pathway Is Involved in (Recurrent) Coronary Disease.
Authors: Arne W.J.H. Dielis, Jose W.P. Govers-Riemslag, Mark Winkens, Patricia Wijers-Holys, Karly Hamulyak, Henri M.H. Spronk, Johannes Waltenberger, Hugo ten Cate
Journal: Blood (2007)
Increased Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Lymphoproliferative Tumors among 14689 First-Degree Relatives of 4488 MGUS Patients in Sweden.
Authors: Ola Landgren, Sigurdur Y. Kristinsson, Lynn R. Goldin, Neil E. Caporaso, Cecilie Blimark, Ulf-Henrik Mellqvist, Anders Wahlin, Magnus Bjorkholm, Ingemar Turesson
Journal: Blood (2007)
Delta Ex6, the Novel Transactivation-Defective Splicing Variant of p53 Gene, Is Differentially Expressed in Patients with Chronic Lymphocytic Leukemia and Confers Accented Proliferative Phenotype in Vitro
Authors: Sona Pekova, Radek Cmejla, Tomas Kozak, Lukas Smolej, Martin Spacek, Miroslav Prucha, Ondrej Hrusak
Journal: Blood (2008)
The HOXA/PBX3 Pathway Is an Attractive Therapeutic Target in MLL-Rearranged Acute Leukemia
Authors: Zejuan Li, Zhiyu Zhang, Yuanyuan Li, Stephen Arnovitz, Ping Chen, Hao Huang, Xi Jiang, Gia-Ming Hong, Chunjiang He, Chong-Zhi Wang, Abdel Elkahloun, Peter J. M. Valk, Konstanze Dohner, Mary Beth Neilly, Lars Bullinger, Ruud Delwel, Bob Lowenberg, Pu Paul Liu, Richard Morgan, Janet D. Rowley, Chun-Su Yuan, Jianjun Chen
Journal: Blood (2012)
Ex Vivo Cytotoxic Activity of Endoribonucleases, Onconase (ranpirnase) and R-Amphinase, against Acute Myeloblastic Leukemia Cells
Authors: Piotr Smolewski, Barbara Cebula, Malgorzata Zwolinska, Anna Linke-Szewczyk, Dominika Wozniak, Kuslima Shogen, Wojciech Ardelt, Zbigniew Darzynkiewicz, Tadeusz Robak
Journal: Blood (2008)
The Novel Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Potent Cytotoxicity in Primary Chronic Lymphocytic Leukemia Cells and a Defective NF-κB Response,
Authors: Sneha V. Gupta, Erin K Hertlein, Jennifer A. Woyach, Ellen J. Sass, Melanie E. Davis, John C. Byrd, David M. Lucas
Journal: Blood (2011)
PI-103, a Dual Inhibitor of Class I Phosphatidylinositide 3-Kinase and mTOR, Has Anti-Leukemic Activity in Acute Myeloid Leukemia.
Authors: Sophie Park, Nicolas Chapuis, Valerie Bardet, Lise Willems, Jerome Tamburini, Zachary A. Knight, Kevan M. Shokat, Nabih Azar, Norbert Ifrah, Francois Dreyfus, Patrick Mayeux, Catherine Lacombe, Didier Bouscary
Journal: Blood (2007)
IL-6 Production by B-CLL Cells Plays a Critical Role in the Inhibition of T Cell Activation and Proliferation and Promotes a Th2 Response in Normal T Lymphocytes.
Authors: Andrea G.S. Buggins, Piers E.M. Patten, Julie Richards, Stephen J. Orr, Ghulam J. Mufti, Nicholas S.B. Thomas, Stephen Devereux
Journal: Blood (2006)
EPID-17. DEMOGRAPHIC AND PRIMARY TUMOR LOCATION PROGNOSTIC FACTORS IN GLIOBLASTOMA SURVIVAL
Authors: Damir Nizamutdinov, Jad Dandashi, Eileen Stock, Samantha Dayawansa, Batool Kirmani, Erxi Wu, Jason Huang, Ekokobe Fonkem
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is an aggressive primary brain tumor with one of the most dismal survival rates. Prognostication of GBM outcomes remains a challenge with controversy over the currently known prognostic factors. This study aims to examine the prognostic value of primary tumor sites and race on survival outcomes. Patient data were obtained from the Scott & White Hospital Brain Tumor Registry (1976 to 2013) and were stratified according to sex, age, ethnicity, primary tumor site, vital status, and survival rate. Of the 645 patients, 580 (89.9%) were diagnosed with GBM, not otherwise specified (NOS), 57 (8.8%) with GBM multiforme, and 8 (1.2%) with giant-cell GBM. The majority were male (53.5%), age 50 or older (78.7%). The white population had the highest GBM prevalence (87.1%) and the lowest overall survival rate vs. all other race groups (6.6% vs. 30.1%, p<0.01). The black population had a relatively low prevalence of GBM (5.9%) and the greatest overall survival rate vs. all others (47.4% vs. 7.3%, p<0.01). Surviving individuals, when compared with deceased, had a greater occurrence of primary tumor sites located in the temporal (25.8% vs. 20.2%, p=0.03), occipital (8.1% vs. 2.9%, p=0.05), and parietal lobes (24.2% vs. 20.8%, p=0.05). The overall survival for men vs. women was (62.9% vs. 37.1%, p=0.12). Black racial background and temporal, occipital, or parietal primary tumor sites are suggestive of positive outcomes and better survival rates in GBM patients. Conversely, white ethnicity with primary tumor sites in the brain overlapping and NOS areas seem to be associated with negative outcomes and decreased survival. Thus, racial background and primary tumor site may be useful prognostic factors in GBM patients.
Patient reported outcomes (PROs) in patients with human papilloma virus (HPV) positive versus negative head and neck cancer (HNC).
Authors: Jessica Ruth Bauman, Areej El-Jawahri, Karen Quinn, Lisa Arcikowski, Gina Chan, Elene Viscosi, Carol Doherty, John Ross Clark, Lori J. Wirth, Jennifer S. Temel
Journal: Journal of Clinical Oncology (2016)

87 Background: HNC caused by HPV has become an epidemic. Treatment for HNC results in a tremendous symptom burden. The impact of HPV-status on quality of life (QOL) and how this effects illness perception and mood has not been described. We sought to explore differences in PROs in patients with HPV + vs. - HNC. Methods: This is a secondary analysis of data from a prospective, longitudinal intervention study of 60 patients with newly diagnosed HNC undergoing concurrent chemoradiation. 30 control patients received standard care followed by 30 intervention patients who received an educational intervention. Satisfaction (information satisfaction questionnaire (ISQ)), mood (Hospital Anxiety and Depression Scale (HADS)), illness perception (Brief Illness Perception Questionnaire (IPQ)), and QOL (MD Anderson Symptom Inventory- Head and Neck (MDASI-HN)) were evaluated at baseline and 3 weeks. Data were analyzed using linear regression models controlling for the effect of the intervention to assess the association between HPV status and changes in PROs. Results: From 8/2014 to 10/2015, we enrolled 60 patients (2 excluded for hospitalization or care elsewhere). 29/58 (50%) had HPV + HNC. 40 (69%) were men. 54 (93%) had stage III/IV disease. Compared to patients with HPV - HNC, patients with HPV + HNC reported an increase in symptom burden, symptom interference, and depressive symptoms, as well as a more threatening illness perception from baseline to 3 weeks. There were no differences in anxiety or satisfaction. Table 1 details the regression models. Conclusions: Patients with HPV + HNC have a larger decrement in QOL during treatment than patients with HPV - HNC, which corresponds to a more threatening illness perception and more depressive symptoms. Interventions tailored to symptom management and mood should be developed for this unique population. [Table: see text]
EVALUATION OF THE EFFECT OF POLICY CHANGE ON PHYSICAL CONTACTS IN YOUTH ICE HOCKEY USING VIDEO ANALYSIS
Authors: Maciej Krolikowski, Brent Hagel, Luc Nadeau, Luz Palacios-Derflingher, Carolyn Emery
Journal: British Journal of Sports Medicine (2017)

Background Policy disallowing body checking in youth ice hockey significantly reduces the risk of injury and concussion. Based on video analysis, frequency and intensity of player to player physical contacts (PCs) are higher in Pee Wee players (ages 11–12) in leagues allowing body checking, however this has not been examined in Bantam leagues (ages 13–14). Objective To determine the association between body checking policy and the frequency and intensity of physical contacts in Bantam ice hockey players (ages 13–14). Design Cohort study. Setting Ice hockey arenas. Participants Thirteen non-elite (lowest 60% by division of play) Bantam ice hockey games in Calgary, Alberta, Canada (2014–15 season) and 13 non-elite games in Vancouver, British Columbia, Canada (2014–15 season) were videotaped. Intervention Policy allowed body checking in Calgary and not Vancouver in the non-elite levels (2014–15). Main Outcome Measurements Incidence rate ratios [IRRs] (adjusted for player position) were estimated using multiple Poisson regression to examine the effect of body checking policy on player-to-player PCs [levels 1–5 with increasing intensity (levels correspond to 4–5 body checking)] and hooking/slashing behaviours. Results Lower rates of higher intensity contacts (levels 4–5 body checking) were observed in Bantam ice hockey players in a league where body checking was disallowed [IRR=0.09; 95% CI: 0.05–0.15]. Players in a league where body checking was disallowed, however, had significantly higher rates of hooking and slashing behaviours [IRR=1.81; 95% CI: 1.33–2.47]. Conclusions Bantam ice hockey players in a league where policy disallowed body checking are at a lower risk of high intensity physical contacts, but commit higher rates of hooking and slashing behaviours. This research informs the mechanisms explaining injury risk reduction related to body checking policy change and have important national public health implications for policy decisions related to rule enforcement in youth sport.
Inhibition of Poly ADP Ribose Polymerase (PARP) Activity Exerts Cytotoxic Effects on Chromosomal Instability Syndrome and Leukaemic Cell Lines: Potential for Anti-Leukaemia Therapy.
Authors: Terry J. Gaymes, S. Shall, Farzin Farzaneh, Ghulam J. Mufti
Journal: Blood (2006)
METB-06. DOWN REGULATION OF PHOSPHOLIPID METABOLISM IS A UNIQUE HALLMARK OF MUTANT IDH1 GLIOMA CELLS
Authors: Pavithra Viswanath, Jose Luis Izquierdo-Garcia, Joanna J. Phillips, Russel O. Pieper, Sabrina Ronen
Journal: Neuro-Oncology (2016)

Aberrant choline metabolism with up-regulated levels of phosphocholine (PC) and phosphoethanolamine (PE) has been recognized as a hallmark of cancer. PC and PE are crucial precursors in the synthesis of the membrane phospholipids, phosphatidylcholine (PtdCho) and phosphatidylethanolamine (PtdEtn). Interestingly, low-grade gliomas carrying the isocitrate dehydrogenase 1 (IDH1) mutation display an unusual metabolic profile with reduced PC and PE levels relative to tumors expressing the wild-type IDH1 enzyme. The goal of the current study was, therefore, to examine the mechanism behind the reduction in PC and PE levels in mutant IDH1 cells using two genetically engineered cell models, a U87 glioblastoma-based model and a normal human astrocyte (NHA) model. We used 13C-magnetic resonance spectroscopy (MRS) to quantify the flux of [1,2-13C]-choline and [1,2-13C]-ethanolamine to 13C-PC and 13C-PE in live cells assembled into a bioreactor. Our results indicated that PC and PE synthesis was reduced in mutant IDH1 cells relative to wild-type in both U87 and NHA models. The activities of choline kinase and ethanolamine kinase, the enzymes responsible for PC and PE synthesis respectively, were concomitantly reduced in mutant IDH1 cells in both models. Consistent with the fact that PC and PE are precursors in phospholipid synthesis, PtdCho and PtdEtn levels were reduced in mutant IDH1 cells relative to wild-type in both U87 and NHA models. Interestingly, cell size was not altered in mutant IDH1 cells despite the reduction in membrane phospholipids. Importantly, pharmacological inhibition of the mutant IDH1 enzyme using a specific inhibitor, AGI-5198, reversed the reduction in choline and ethanolamine kinase activity and resulted in increased PC and PE synthesis as well as increased PtdCho and PtdEtn levels in mutant IDH1 cells. Taken together, our study points to unusual remodeling of phospholipid metabolism in mutant IDH1 cells, a finding with important therapeutic implications.
STMC-11. ANALYSIS OF miRNA EXPRESSION PROFILE REGULATED BY SOX2 IN GLIOMA STEM-LIKE CELLS
Authors: Arlet Maria Acanda de la Rocha, Hernando Lopez-Bertoni, Naiara Martínez-Vélez, Marisol González-Huarriz, John Laterra, Marta M Alonso Roldán
Journal: Neuro-Oncology (2016)

Glioblastoma is the most common malignant primary brain tumors in adults and despite maximum therapeutic efforts the prognosis is dismal. Glioblastoma is composed by heterogeneous cell populations, among which the glioma stem-like cells (GSCs) plays an especially important role in tumor cell self-renewal and the ability to initiate and drive tumor growth and recurrence. The transcription factor SOX2 is enriched in GSCs where it controls stemness, invasion and maintenance of tumorigenicity. Therefore, understanding the molecular mechanisms governed by SOX2 in GSCs is crucial to developing targeted therapies against this recalcitrant population. In this study using a miRNA array we identified and validated a miRNA profile regulated by SOX2 in GSCs. Among these miRNAs, miR-425-5p emerged as a robust and significant validated candidate for further study. The expression of miR-425 was significantly over-expressed in 15 clinical glioblastoma specimens compared with a human RNA brain reference sample showing a positive correlation with SOX2 expression levels (R2=0.7; P= 0.01). In silico analysis of the miR-425-5p promoter region identified potential binding sites for SOX2. qChIP experiments confirmed the binding of SOX2 to the miR-425-5p promoter, suggesting that SOX2 directly activate miR-425-5p expression. To study the role of miR-425-5p in GSCs biology we performed loss of function experiments using a lentiviral miR-425-5p sponge. Inhibiting miR-425-5p in multiple GSCs affected cell viability, promoted a G1/S arrest, inhibited neurosphere formation and invasion, and caused cell death. Effects on tumor propagating capacity in vivo are currently on going. Finally, applying several bioinformatic programs (miRDB, miRTarBase, PicTar, and TargetScan) we identified potential target genes for miR-425, and have validated them in different GSC lines. This study suggests that miR-425-5p may act as a novel oncogene, providing future novel diagnostic and therapeutic strategies for glioblastoma.
Alleviating financial burden for cancer patients in clinical trials.
Authors: Ryan David Nipp, Elizabeth Powell, Daniel Finkelstein, Karen Marie Winkfield, Sanja Percac-Lima, Bruce Allan Chabner, Beverly Moy
Journal: Journal of Clinical Oncology (2014)

10 Background: Financial barriers may prevent cancer patients from enrolling into clinical trials. This financial burden has yet to be fully explored. The goal of this study is to establish the feasibility of a financial assistance program for cancer patients enrolled in clinical trials and to analyze patient characteristics associated with financial aid requests. Methods: We performed a cross-sectional analysis of cancer clinical trial patients who registered for a financial assistance program at a tertiary cancer center. This program is designed to fund non-clinical expenses related to clinical trial participation (e.g. travel, lodging). Patients were referred to the program by their provider and enrolled if they expressed interest. After registration, applicants were required to request reimbursement monthly in order to receive funding. Descriptive statistics and univariate analyses compared characteristics of patients who requested funding vs. those who did not. Results: From November 2013 to April 2014, a total of 86 participants enrolled into the financial assistance program; 43 received funds and 43 did not. Most patients were &lt;65 years old (73%), female (70%), white (86%), married (67%), and enrolled in a phase 1 trial (69%). Patients with lower incomes were more likely to request funds than those with incomes &gt; $75,000 (61% vs. 38%, p=0.01). Patients currently employed were more likely to pursue funds than disabled or unemployed patients (58% vs. 21%, p&lt;0.01). Out-of-state patients were more likely to ask for funds than in-state patients (64% vs.19%, p&lt;0.01). Patients who requested funds were less likely to have disease progression after enrollment than those who did not request funds (19% vs. 42%, p=0.03). Conclusions: Enrolling clinical trial participants onto a financial assistance program is both feasible and informative. The patients who requested financial aid in our program were more likely to have lower incomes, remain employed, and reside out of state. Those who requested funding were less likely to have disease progression after program enrollment. Future efforts should continue to explore and improve interventions aimed to alleviate the financial burden experienced by cancer patients enrolled in clinical trials.
Identification of diverse astrocyte populations and their malignant analogs
Authors: Chia-Ching John Lin, Kwanha Yu, Asante Hatcher, Teng-Wei Huang, Hyun Kyoung Lee, Jeffrey Carlson, Matthew C Weston, Fengju Chen, Yiqun Zhang, Wenyi Zhu, Carrie A Mohila, Nabil Ahmed, Akash J Patel, Benjamin R Arenkiel, Jeffrey L Noebels, Chad J Creighton, Benjamin Deneen
Journal: Nature Neuroscience (2017)
Whole Genome Sequencing Reveals a Widely Expressed Mutation (MYD88 L265P) with Oncogenic Activity in Waldenstrom's Macroglobulinemia
Authors: Steven P Treon, Lian Xu, Yangsheng Zhou, Xia Liu, Guang Yang, Yang Cao, Christina Hanzis, Patricia Sheehy, Robert Manning, Christopher J Patterson, Jason M Laramie, Donald A Skifter, Stephen E Lincoln, Zachary Hunter
Journal: Blood (2011)
The diagnostic utility of serum assays for total IgG4 and specific IgG4 antibodies to cow's milk proteins in children with eosinophilic esophagitis: Comparison with an unselected birth cohort
Authors: Alexander J. Schuyler, Elizabeth A. Erwin, Emily Oken, Sheryl Rifas-Shiman, Jonas Lidholm, Jeffrey Wilson, Anubha Tripathi, Lisa J. Workman, Diane R. Gold, Thomas A.E. Platts-Mills
Journal: Journal of Allergy and Clinical Immunology (2017)
Wilms Tumor 1 Gene Mutations in Adult Acute T-Lymphoblastic Leukemia
Authors: Sandra Heesch, Nicola Goekbuget, Jutta Ortiz Tanchez, Cornelia Schlee, Stefan Schwartz, Thomas Burmeister, Dieter Hoelzer, Eckhard Thiel, Wolf K Hofmann, Claudia D Baldus
Journal: Blood (2008)
Adipose tissue B2 cells promote insulin resistance through leukotriene LTB4/LTB4R1 signaling
Authors: Wei Ying, Joshua Wollam, Jachelle M. Ofrecio, Gautam Bandyopadhyay, Dalila El Ouarrat, Yun Sok Lee, Da Young Oh, Pingping Li, Olivia Osborn, Jerrold M. Olefsky
Journal: Journal of Clinical Investigation (2017)

Tissue inflammation is a key component of obesity-induced insulin resistance, with a variety of immune cell types accumulating in adipose tissue. Here, we have demonstrated increased numbers of B2 lymphocytes in obese adipose tissue and have shown that high-fat diet-induced (HFD-induced) insulin resistance is mitigated in B cell-deficient (Bnull) mice. Adoptive transfer of adipose tissue B2 cells (ATB2) from wild-type HFD donor mice into HFD Bnull recipients completely restored the effect of HFD to induce insulin resistance. Recruitment and activation of ATB2 cells was mediated by signaling through the chemokine leukotriene B4 (LTB4) and its receptor LTB4R1. Furthermore, the adverse effects of ATB2 cells on glucose homeostasis were partially dependent upon T cells and macrophages. These results demonstrate the importance of ATB2 cells in obesity-induced insulin resistance and suggest that inhibition of the LTB4/LTB4R1 axis might be a useful approach for developing insulin-sensitizing therapeutics.
Oxidative Stress Is Increased in Chronic Idiopathic Myelofibrosis (CIMF) Patients, and Is Associated with High Levels of Homocysteine (Hcy) and Depletion of Holotranscobalamin (holoTC).
Authors: Nicola S. Fracchiolla, Fabrizia Bamonti Catena, Claudia Vener, Rossella Calori, Cristina Novembrino, Giorgio Lambertenghi Deliliers
Journal: Blood (2006)